





Asthma Committee meeting 13

Date: 05/07/2023

Location: Virtual meeting

Minutes: Final



Committee members present:		
Lynn Elsey	Present for notes 1-7	
Matthew Doyle	Present for notes 1-7	
Kevin Gruffydd-Jones	Present for notes 1-7	
Stephen Fowler (Topic Adviser)	Present for notes 1-7	
Natalie Harper	Present for notes 1-7	
Sheba Joseph	Present for notes 1-7	
Alan MacDonald (Co-Chair)	Present for notes 1-7	
Kenneth Macleod	Present for notes 1-7	
Andrew Molyneux	Present for notes 1-7	
Elia Monterio	Present for notes 1-7	
Kay Roy	Present for notes 3-7	
Ian Sinha (Topic Adviser)	Present for notes 1-7	
Phil Taverner	Present for notes 1-7	
Edwina Wooler	Present for notes 1-7	

In attendance:		
Victoria Axe	Guideline Commissioning Manager	Present for notes 1-7
Amy Crisp	Senior Project Manager	Present for notes 1-7
Bernard Higgins	Clinical Director	Present for notes 1-7
Qudsia Malik	Technical Analyst	Present for notes 1-3
Alfredo Mariani	Senior Health Economist	Present for notes 1-7







Annette Mead	Senior Medical Editor	Present for notes 1-7
Lisa Miles	Technical Analyst	Present for notes 1-7
Louisa Regan	Implementation Manager	Present for notes 3-7
Toby Sands	Technical Analyst	Present for notes 1-7
Melina Vasileou	Technical Analyst	Present for notes 1-7
Catriona Vernal	SIGN Programme Manager	Present for notes 1-7

Apologies:

1. Welcome and objectives for the meeting

The Co-Chair welcomed the Committee members and attendees to the thirteenth Asthma guideline committee meeting.

The Co-Chair informed the Committee that no apologies had been received.

The Co-Chair outlined the objectives of the meeting, which included Symptoms diary monitoring and pulmonary function monitoring.

2. Confirmation of matter under discussion, and declarations of interest

The Co-Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were as above.

The Co-Chair asked everyone to verbally declare any interests that have arisen since the last meeting. There were no new declarations of interest.

3. Evidence review

QM and AMa presented the following evidence review to the committee:

2.2 Pulmonary function monitoring

The committee discussed the evidence presented.

4. Evidence review

LM and AMa presented the following evidence review to the committee:

2.1 Symptoms diary monitoring







The committee discussed the evidence presented.

5. Evidence review

AMa presented an update to the following evidence review to the committee:

• 2.4 Risk stratification

The committee discussed the evidence presented.

6. Health Economics

AMa updated the committee on the health economics modelling work.

7. Any other business

None.

Date of next meeting: 08/08/2023

Location of next meeting: Virtual meeting